Abound Wealth Management’s Parker-Hannifin PH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.3K Sell
16
-13
-45% -$11.9K ﹤0.01% 413
2026
Q1
$25.6K Buy
29
+4
+16% +$3.79K 0.01% 346
2025
Q4
$21.7K Buy
25
+1
+4% +$818 0.01% 347
2025
Q3
$18.4K Buy
24
+1
+4% +$738 ﹤0.01% 378
2025
Q2
$16.4K Sell
23
-11
-32% -$6.95K ﹤0.01% 364
2025
Q1
$20.9K Sell
34
-5
-13% -$3.27K 0.01% 285
2024
Q4
$24.8K Buy
39
+1
+3% +$662 0.01% 252
2024
Q3
$24.3K Buy
38
+12
+46% +$6.82K 0.01% 257
2024
Q2
$13.4K Sell
26
-2
-7% -$1.07K ﹤0.01% 322
2024
Q1
$15.3K Buy
28
+2
+8% +$1.02K 0.01% 300
2023
Q4
$12K Buy
26
+3
+13% +$1.25K ﹤0.01% 344
2023
Q3
$8.98K Buy
23
+1
+5% +$402 ﹤0.01% 351
2023
Q2
$8.6K Buy
22
+5
+29% +$1.69K ﹤0.01% 369
2023
Q1
$5.73K Hold
17
﹤0.01% 376
2022
Q4
$4.96K Buy
17
+10
+143% +$2.86K ﹤0.01% 358
2022
Q3
$1.71K Buy
+7
New +$1.89K ﹤0.01% 511

Other funds holding PH

Abound Wealth Management's PH Position: Q2 2026 in Review

Abound Wealth Management reduced its Parker-Hannifin (PH) stake by 45% in Q2 2026, selling an estimated $11.9K and leaving 16 shares worth $15.3K. The position accounts for ﹤0.01% of the portfolio, ranked #413.

Abound Wealth Management first reported a position in PH in Q3 2022 and has held it in 16 quarters since. The position peaked at $25.6K in Q1 2026. 360 funds tracked by Wall St. Rank hold PH as of Q2 2026.

  • Abound Wealth Management held 16 shares of Parker-Hannifin worth $15.3K as of Q2 2026.
  • Abound Wealth Management sold 13 Parker-Hannifin shares in Q2 2026, an estimated $11.9K.
  • Parker-Hannifin made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #413 holding.
  • Abound Wealth Management first reported a position in Parker-Hannifin in Q3 2022 and has held it in 16 quarters since.
  • Abound Wealth Management's Parker-Hannifin position peaked at $25.6K in Q1 2026.
  • 360 funds tracked by Wall St. Rank held Parker-Hannifin as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.